A Synthetic Tetramer of Galectin-1 and Galectin-3 Amplifies Pro-apoptotic Signaling by Integrating the Activity of Both Galectins.

galectin-1 galectin-3 glycobiology protein engineering protein-carbohydrate binding

Journal

Frontiers in chemistry
ISSN: 2296-2646
Titre abrégé: Front Chem
Pays: Switzerland
ID NLM: 101627988

Informations de publication

Date de publication:
2019
Historique:
received: 27 08 2019
accepted: 12 12 2019
entrez: 31 1 2020
pubmed: 31 1 2020
medline: 31 1 2020
Statut: epublish

Résumé

Galectin-1 (G1) and galectin-3 (G3) are carbohydrate-binding proteins that can signal apoptosis in T cells. We recently reported that a synthetic tetramer with two G1 and two G3 domains ("G1/G3 Zipper") induces Jurkat T cell death more potently than G1. The pro-apoptotic signaling pathway of G1/G3 Zipper was not elucidated, but we hypothesized based on prior work that the G1 domains acted as the signaling units, while the G3 domains served as anchors that increase glycan-binding affinity. To test this, here we studied the involvement of different cell membrane glycoproteins and intracellular mediators in pro-apoptotic signaling via G1/G3 Zipper, G1, and G3. G1/G3 Zipper induced Jurkat T cell death more potently than G1 and G3 alone or in combination. G1/G3 Zipper, G1, and G3 increased caspase-8 activity, yet only G1 and G3 depended on it to induce cell death. G3 increased caspase-3 activity more than G1/G3 Zipper and G1, while all three galectin variants required it to induce cell death. JNK activation had similar roles downstream of G1/G3 Zipper, G1, and G3, whereas ERK had differing roles. CD45 was essential for G1 activity, and was involved in signaling via G1/G3 Zipper and G3. CD7 inhibited G1/G3 Zipper activity at low galectin concentrations but not at high galectin concentrations. In contrast, CD7 was necessary for G1 and G3 signaling at low galectin concentration but antagonistic at high galectin concentrations. Collectively, these observations suggest that G1/G3 Zipper amplifies pro-apoptotic signaling through the integrated activity of both the G1 and G3 domains.

Identifiants

pubmed: 31998689
doi: 10.3389/fchem.2019.00898
pmc: PMC6966408
doi:

Types de publication

Journal Article

Langues

eng

Pagination

898

Subventions

Organisme : NIDCR NIH HHS
ID : R01 DE027301
Pays : United States
Organisme : NIBIB NIH HHS
ID : R03 EB019684
Pays : United States

Informations de copyright

Copyright © 2020 Farhadi, Fettis, Liu and Hudalla.

Références

J Immunol. 1999 Oct 1;163(7):3801-11
pubmed: 10490978
Front Immunol. 2014 Jun 18;5:284
pubmed: 24995007
Eur J Immunol. 2002 Apr;32(4):1129-38
pubmed: 11932920
J Virol. 2012 Oct;86(19):10606-20
pubmed: 22811539
Exp Hematol. 2001 Apr;29(4):477-89
pubmed: 11301188
J Biomed Sci. 2005;12(1):13-29
pubmed: 15864736
J Biol Chem. 2005 Feb 25;280(8):6969-85
pubmed: 15556941
Trends Endocrinol Metab. 2012 Jan;23(1):23-31
pubmed: 22036528
Nat Cell Biol. 2003 Jul;5(7):647-54
pubmed: 12792650
Biomater Sci. 2019 Apr 23;7(5):1852-1862
pubmed: 30899922
Methods Enzymol. 2003;363:499-518
pubmed: 14579599
J Immunol. 2006 Jan 15;176(2):778-89
pubmed: 16393961
J Immunol. 2010 Oct 15;185(8):4659-72
pubmed: 20844192
Gastroenterology. 2003 May;124(5):1381-94
pubmed: 12730878
J Immunol. 2008 Mar 1;180(5):3091-102
pubmed: 18292532
Oncotarget. 2017 Jul 25;8(30):49824-49838
pubmed: 28548942
J Immunol. 1997 Nov 15;159(10):4762-71
pubmed: 9366400
J Virol. 2011 Nov;85(22):11742-51
pubmed: 21880749
Bioconjug Chem. 2018 Jul 18;29(7):2489-2496
pubmed: 29920086
Nat Rev Immunol. 2009 May;9(5):338-52
pubmed: 19365409
Cell Death Dis. 2010;1:e23
pubmed: 21364631
J Immunol. 2012 Apr 1;188(7):2991-9
pubmed: 22357632
J Biol Chem. 1996 Nov 1;271(44):27686-95
pubmed: 8910360
Joint Bone Spine. 2017 Jan;84(1):15-20
pubmed: 27238188
J Clin Cell Immunol. 2013 Sep 30;4(5):null
pubmed: 24416634
Immunol Lett. 1999 Apr 15;67(3):193-202
pubmed: 10369126
Mol Immunol. 2007 Jan;44(4):506-13
pubmed: 16581128
Nat Commun. 2018 Nov 22;9(1):4943
pubmed: 30467349
Cell Mol Bioeng. 2015 Sep 1;8(3):471-487
pubmed: 26495044
J Immunol. 2001 Nov 15;167(10):5697-707
pubmed: 11698442
Histochem Cell Biol. 2008 May;129(5):599-609
pubmed: 18288482
Exp Biol Med (Maywood). 2016 May;241(10):1074-83
pubmed: 27229902
Annu Rev Immunol. 2016 May 20;34:243-64
pubmed: 26907217
Cell Death Differ. 2004 Dec;11(12):1277-86
pubmed: 15297883
J Immunol. 2000 Sep 1;165(5):2331-4
pubmed: 10946254
Am J Pathol. 1996 May;148(5):1661-70
pubmed: 8623933
Glycobiology. 2011 Jan;21(1):6-12
pubmed: 20864568
Oncogene. 2008 Oct 20;27(48):6245-51
pubmed: 18931691
Genes Cancer. 2017 Sep;8(9-10):682-694
pubmed: 29234486
J Biol Chem. 2008 Apr 11;283(15):10109-23
pubmed: 18216021
Biochimie. 2001 Jul;83(7):667-76
pubmed: 11522396
Cancer Res. 2003 Dec 1;63(23):8302-11
pubmed: 14678989
Front Immunol. 2012 Jul 13;3:199
pubmed: 22811679
J Exp Med. 1999 Aug 2;190(3):385-98
pubmed: 10430627
Cell. 1998 Aug 21;94(4):491-501
pubmed: 9727492
J Infect Dis. 2013 Mar 15;207(6):947-56
pubmed: 23255567
Clin Exp Immunol. 2002 May;128(2):255-66
pubmed: 11985515

Auteurs

Shaheen A Farhadi (SA)

J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States.

Margaret M Fettis (MM)

J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States.

Renjie Liu (R)

J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States.

Gregory A Hudalla (GA)

J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States.

Classifications MeSH